1887

Chapter 39 : Molecular Diagnostics and the Changing Face of Point-of-Care

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Molecular Diagnostics and the Changing Face of Point-of-Care, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819071/9781555819088.ch39-1.gif /docserver/preview/fulltext/10.1128/9781555819071/9781555819088.ch39-2.gif

Abstract:

diagnostics (IVDs) are undergoing an evolution that is being driven by nucleic acid–based molecular detection technologies, from fully automated, multistep miniaturized platforms that integrate sample prep, detection, and signal amplification into single-step cassettes processed on handheld or portable instrumentation (1, 2), to novel real-time detection chemistries that are platform-agnostic and allow high target multiplexing (3). With simplified laboratory requirements, portable equipment and wireless links to remote health care services, these sophisticated technology platforms have the potential to revolutionize patient testing, putting actionable information rapidly into the hands of the treating clinician during the patient encounter, regardless of where the interaction occurs.

Citation: Dolinger D, Whalen A. 2016. Molecular Diagnostics and the Changing Face of Point-of-Care, p 545-555. In Persing D, Tenover F, Hayden R, Ieven M, Miller M, Nolte F, Tang Y, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555819071.ch39
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555819071.ch39
1. Chin CD, Linder V, Sia SK. 2012. Commercialization of microfluidic point-of-care diagnostic devices. Lab Chip 12:21182134[CrossRef].[PubMed]
2. Dheda K, Ruhwald M, Theron G, Peter J, Yam WC. 2013. Point-of-care diagnosis of tuberculosis: past, present and future. Respirology 18:217232[CrossRef].[PubMed]
3. Estrade C, Sahli R, McAdam AJ. 2014. Comparison of Seegene Anyplex II HPV28 with the PGMY-CHUV assay for human papillomavirus genotyping. J Clin Microbiol 52:607612[CrossRef].[PubMed]
4. Chan CPY, Mak WC, Cheung KY, Sin KK, Yu CM, Rainer TH, Renneberg R. 2013. Evidence-based point-of-care diagnostics: current status and emerging technologies. Annu Rev Anal Chem (Palo Alto, Calif) 6:191211[CrossRef].[PubMed]
5. Collins FS. 2011. Genome-sequencing anniversary. Faces of the genome. Science 331:546[CrossRef].[PubMed]
6. Veigas B, Fernandes AR, Baptista PV. 2014. AuNPs for identification of molecular signatures of resistance. Front Microbiol 5:455. doi:10.3389/fmicb.2014.00455
7. Pedrosa P, Veigas B, Machado D, Couto I, Viveiros M, Baptista PV. 2014. Gold nanoprobes for multi loci assessment of multi-drug resistant tuberculosis. Tuberculosis (Edinb) 94:332337[CrossRef].[PubMed]
8. Hartman MR, Ruiz RC, Hamada S, Xu C, Yancey KG, Yu Y, Han W, Luo D. 2013. Point-of-care nucleic acid detection using nanotechnology. Nanoscale 5:1014110154[CrossRef].[PubMed]
9. Bahadur D, Dravid VP. 2011. Hybrid nanostructures for diagnostics and therapeutics. Adv Drug Deliv Rev 63:12271237[CrossRef].[PubMed]
10. Lee JH, Yigit MV, Mazumdar D, Lu Y. 2010. Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates. Adv Drug Deliv Rev 62:592605[CrossRef].[PubMed]
11. Vella SJ, Beattie P, Cademartiri R, Laromaine A, Martinez AW, Phillips ST, Mirica KA, Whitesides GM. 2012. Measuring markers of liver function using a micropatterned paper device designed for blood from a fingerstick. Anal Chem 84:28832891[CrossRef].[PubMed]
12. Ducree J (ed). 2012. Special Issue: Microfluidic Lab-on-a-Chip Platforms for High-Performance Diagnostics. Diagnostics 2:1.
13. Venkatesan BM, Bashir R. 2011. Nanopore sensors for nucleic acid analysis. Nat Nanotechnol 6:615624[CrossRef].[PubMed]
14. Wang Y, Zheng D, Tan Q, Wang MX, Gu LQ. 2011. Nanopore-based detection of circulating microRNAs in lung cancer patients. Nat Nanotechnol 6:668674[CrossRef].[PubMed]
15. Boyle DS, McNerney R, Teng Low H, Leader BT, Pérez-Osorio AC, Meyer JC, O'Sullivan DM, Brooks DG, Piepenburg O, Forrest MS. 2014. Rapid detection of Mycobacterium tuberculosis by recombinase polymerase amplification. PLoS One 9:e103091[CrossRef].[PubMed]
16. Craw P, Balachandran W. 2012. Isothermal nucleic acid amplification technologies for point-of-care diagnostics: a critical review. Lab Chip 12:24692486[CrossRef].[PubMed]
17. MEDLINEplus. Point-of-Care Systems. National Library of Medicine, Bethesda, MD. http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?mode=&index=17762&view=concept
18. Stedman TL (ed). 2008. Stedman's Medical Dictionary for the Health Professions and Nursing. Wolters Kluwer Health, Philadelphia, PA.
19. Collopy KT, Kivlehan SM, Snyder S. 2014. What's the point of point-of-care testing? Understanding the potential of this evolving capability. EMS World 43:3442.
20. Lewandrowski K, Gregory K, Macmillan D. 2011. Assuring quality in point-of-care testing: evolution of technologies, informatics, and program management. Arch Pathol Lab Med 135:14051414[CrossRef].[PubMed]
21. St John A, Price CP. 2013. Economic evidence and point-of-care testing. Clin Biochem Rev 34:6174.[PubMed]
22. Jenson A, Dize L, Mkocha H, Munoz B, Lee J, Gaydos C, Quinn T, West SK. 2013. Field evaluation of the Cepheid GeneXpert Chlamydia trachomatis assay for detection of infection in a trachoma endemic community in Tanzania. PLoS Negl Trop Dis 7:e2265[CrossRef].[PubMed]
23. Gubbins PO, Klepser ME, Dering-Anderson AM, Bauer KA, Darin KM, Klepser S, Matthias KR, Scarsi K. 2003. 2014. Point-of-care testing for infectious diseases: opportunities, barriers, and considerations in community pharmacy. J Am Pharm Assoc 54:163171[CrossRef].
24. Laurence CO, Moss JR, Briggs NE, Beilby JJ, PoCT Trial Management Group. 2010. The cost-effectiveness of point of care testing in a general practice setting: results from a randomised controlled trial. BMC Health Serv Res 10:165176.
25. Bossmann SH, Troyer DL. 2013. Point-of-care routine rapid screening: the future of cancer diagnosis? Expert Rev Mol Diagn 13:107109[CrossRef].[PubMed]
26. Burn J. 2013. Company profile: QuantuMDx group limited. Pharmacogenomics 14:10111015[CrossRef].[PubMed]
27. Holguín A, Gutiérrez M, Portocarrero N, Rivas P, Baquero M. 2009. Performance of OraQuick Advance Rapid HIV-1/2 Antibody Test for detection of antibodies in oral fluid and serum/plasma in HIV-1+ subjects carrying different HIV-1 subtypes and recombinant variants. J Clin Virol 45:150152[CrossRef].[PubMed]
28. Delaney KP, Branson BM, Uniyal A, Kerndt PR, Keenan PA, Jafa K, Gardner AD, Jamieson DJ, Bulterys M. 2006. Performance of an oral fluid rapid HIV-1/2 test: experience from four CDC studies. AIDS 20:16551660[CrossRef].[PubMed]
29. Duong YT, Mavengere Y, Patel H, Moore C, Manjengwa J, Sibandze D, Rasberry C, Mlambo C, Li Z, Emel L, Bock N, Moore J, Nkambule R, Justman J, Reed J, Bicego G, Ellenberger DL, Nkengasong JN, Parekh BS. 2014. Poor performance of the determine HIV-1/2 Ag/Ab combo fourth-generation rapid test for detection of acute infections in a National Household Survey in Swaziland. J Clin Microbiol 52:37433748[CrossRef].[PubMed]
30. Walensky RP, Bassett IV. 2011. HIV self-testing and the missing linkage. PLoS Med 8:e1001101.
31. MacPherson P, Corbett EL, Makombe SD, van Oosterhout JJ, Manda E, Choko AT, Thindwa D, Squire SB, Mann GH, Lalloo DG. 2012. Determinants and consequences of failure of linkage to antiretroviral therapy at primary care level in Blantyre, Malawi: a prospective cohort study. PLoS One 7:e44794[CrossRef].[PubMed]
32. Klarkowski D, O'Brien DP, Shanks L, Singh KP. 2014. Causes of false-positive HIV rapid diagnostic test results. Expert Rev Anti Infect Ther 12:4962[CrossRef].[PubMed]
33. Cummings K. 2013. New HIV Detection and Confirmation Testing Platforms. Microbicide Trial Network. http://www.mtnstopshiv.org/sites/default/files/attachments/NL%20New%20HIV%20Testing%20Platforms%20-%20K%20Cummings.pdf
34. Tang Y-W, Ou C-Y.2012. Past, present and future molecular diagnosis and characterization of human immunodeficiency virus infections. Emerg Microbes Infect 1:e19.
35. Chantry CJ, Cooper ER, Pelton SI, Zorilla C, Hillyer GV, Diaz C. 1995. Seroreversion in human immunodeficiency virus-exposed but uninfected infants. Pediatr Infect Dis J 14:382387[CrossRef].[PubMed]
36. World Health Organization. 2011. Commercial Serological Tests for Diagnosis of Tuberculosis: Policy Statement. WHO, Geneva, Switzerland.
37. van Dommelen L, van Tiel FH, Ouburg S, Brouwers EE, Terporten PH, Savelkoul PH, Morré SA, Bruggeman CA, Hoebe CJ. 2010. Alarmingly poor performance in Chlamydia trachomatis point-of-care testing. Sex Transm Infect 86:355359.
38. Mouatcho JC, Goldring JP. 2013. Malaria rapid diagnostic tests: challenges and prospects. J Med Microbiol 62:14911505[CrossRef].[PubMed]
39. World Health Organization. 2013. 2014. Malaria Rapid Diagnostic Test Performance: Results of WHO Product Testing of Malaria RDTs: Round 5. WHO, Geneva, Switzerland.
40. Counihan H, Harvey SA, Sekeseke-Chinyama M, Hamainza B, Banda R, Malambo T, Masaninga F, Bell D. 2012. Community health workers use malaria rapid diagnostic tests (RDTs) safely and accurately: results of a longitudinal study in Zambia. Am J Trop Med Hyg 87:5763[CrossRef].[PubMed]
41. Pilcher CD, Louie B, Facente S, Keating S, Hackett J Jr, Vallari A, Hall C, Dowling T, Busch MP, Klausner JD, Hecht FM, Liska S, Pandori MW. 2013. Performance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco. PLoS One 8:e80629[CrossRef].[PubMed]
42. Kettler H, White K, Hawkes S. 2004. Mapping the landscape of diagnostics for sexually transmitted infections (STI). UNICEF/UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR). TDR/STI/IDE/04.1, http://www.who.int/tdr/publications/documents/mapping-landscape-sti.pdf?ua=1.
43. Tucker JD, Bien CH, Peeling RW. 2013. Point-of-care testing for sexually transmitted infections: recent advances and implications for disease control. Curr Opin Infect Dis 26:7379[CrossRef].[PubMed]
44. Peeling RW, Holmes KK, Mabey D, Ronald A. 2006. Rapid tests for sexually transmitted infections (STIs): the way forward. Sex Transm Infect 82(Suppl 5):v1v6[CrossRef].[PubMed]
45. Lehe JD, Sitoe NE, Tobaiwa O, Loquiha O, Quevedo JI, Peter TF, Jani IV. 2012. Evaluating operational specifications of point-of-care diagnostic tests: a standardized scorecard. PLoS One 7:e47459[CrossRef].[PubMed]
46. Peeling RW, McNerney R. 2014. Emerging technologies in point-of-care molecular diagnostics for resource-limited settings. Expert Rev Mol Diagn 14:525534[CrossRef].[PubMed]
47. Niemz A, Boyle DS. 2012. Nucleic acid testing for tuberculosis at the point-of-care in high-burden countries. Expert Rev Mol Diagn 12:687701[CrossRef].[PubMed]
48. Pai NP, Vadnais C, Denkinger C, Engel N, Pai M. 2012. Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLoS Med 9:e1001306[CrossRef].[PubMed]
49. Wang H, Silva A, Ho CM. 2013. When medicine meets engineering: paradigm shifts in diagnostics and therapeutics. Diagnostics 3:126154[CrossRef].
50. Gaydos CA, Van Der Pol B, Jett-Goheen M, Barnes M, Quinn N, Clark C, Daniel GE, Dixon PB, Hook EW III, CT/NG Study Group. 2013. Performance of the Cepheid CT/NG Xpert Rapid PCR Test for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol 51:16661672[CrossRef].[PubMed]
51. Centers for Disease Control and Prevention (CDC). 2013. Availability of an assay for detecting Mycobacterium tuberculosis, including rifampin-resistant strains, and considerations for its use—United States, 2013. MMWR Morb Mortal Wkly Rep 62:821827.[PubMed]
52. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT, Blakemore R, Worodria W, Gray C, Huang L, Caceres T, Mehdiyev R, Raymond L, Whitelaw A, Sagadevan K, Alexander H, Albert H, Cobelens F, Cox H, Alland D, Perkins MD. 2011. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377:14951505[CrossRef].[PubMed]
53. Castan P, de Pablo A, Fernández-Romero N, Rubio JM, Cobb BD, Mingorance J, Toro C, Moser SA. 2014. Point-of-care system for detection of Mycobacterium tuberculosis and rifampin resistance in sputum samples. J Clin Microbiol 52:502507[CrossRef].[PubMed]
54. Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, Cuevas LE, McHugh TD, Zijenah L, Kapata N, Abubakar I, McNerney R, Hoelscher M, Memish ZA, Migliori GB, Kim P, Maeurer M, Schito M, Zumla A. 2013. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 13:349361.
55. Walusimbi S, Bwanga F, De Costa A, Haile M, Joloba M, Hoffner S. 2013. Meta-analysis to compare the accuracy of GeneXpert, MODS and the WHO 2007 algorithm for diagnosis of smear-negative pulmonary tuberculosis. BMC Infect Dis 13:507520[CrossRef].[PubMed]
56. Evans CA. 2011. GeneXpert—a game-changer for tuberculosis control? PLoS Med 8:e1001064[CrossRef].[PubMed]
57. NCT 02252198. 2014. Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests (FIND). U.S. National Institutes of Health. https://clinicaltrials.gov/ct2/results/details?term=NCT+02252198.
58. US Food and Drug Administration. 2014. Administrative Procedures for CLIA Categorization. Guidance for Industry and Food and Drug Administration Staff. OMB Con No. 0910-0607.
59. Pai NP, Pai M. 2012. Point-of-care diagnostics for HIV and tuberculosis: landscape, pipeline, and unmet needs. Discov Med 13:3545.[PubMed]
60. Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, Hase T. 2000. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res 28:E63[CrossRef].[PubMed]
61. Cao Y, Kim HJ, Li Y, Kong H, Lemieux B. 2013. Helicase-dependent amplification of nucleic acids. Curr Protoc Mol Biol. 104:15.11:15.11.115.11.12.
62. Li Y, Cu YT, Luo D. 2005. Multiplexed detection of pathogen DNA with DNA-based fluorescence nanobarcodes. Nat Biotechnol 23:885889[CrossRef].[PubMed]
63. Veigas B, Fernandes AR, Baptista PV. 2014. AuNPs for identification of molecular signatures of resistance. Front Microbiol 5:455[CrossRef].[PubMed]
64. Holland CA, Kiechle FL. 2005. Point-of-care molecular diagnostic systems—past, present and future. Curr Opin Microbiol 8:504509[CrossRef].[PubMed]
65. Myers FB, Henrikson RH, Bone JM, Lee LP. 2013. A handheld point-of-care genomic diagnostic system. PLoS One 8:e70266. (Erratum, doi:10.1371/annotation/902dc1bb-9ed7-4e91-a550-0f0a87ce17ba).
66. Johansen Taber KA, Dickinson BD, Wilson M. 2014. The promise and challenges of next-generation genome sequencing for clinical care. JAMA Intern Med 174:275280[CrossRef].[PubMed]
67. Pant S, Weiner R, Marton MJ. 2014. Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. Front Oncol 4:78[CrossRef].[PubMed]
68. Babady NE. 2013. The FilmArray® respiratory panel: an automated, broadly multiplexed molecular test for the rapid and accurate detection of respiratory pathogens. Expert Rev Mol Diagn 13:779788[CrossRef].[PubMed]
69. Govindarajan AV, Ramachandran S, Vigil GD, Yager P, Böhringer KF. 2012. A low cost point-of-care viscous sample preparation device for molecular diagnosis in the developing world; an example of microfluidic origami. Lab Chip 12:174181[CrossRef].[PubMed]
70. World Health Organization. 2011. Rapid Implementation of the Xpert MTB/RIF diagnostic test. WHO Library, Geneva, Switzerland.
71. Mudanyali O, Dimitrov S, Sikora U, Padmanabhan S, Navruz I, Ozcan A. 2012. Integrated rapid-diagnostic-test reader platform on a cellphone. Lab Chip 12:26782686[CrossRef].[PubMed]
72. Chin CD, Cheung YK, Laksanasopin T, Modena MM, Chin SY, Sridhara AA, Steinmiller D, Linder V, Mushingantahe J, Umviligihozo G, Karita E, Mwambarangwe L, Braunstein SL, van de Wijgert J, Sahabo R, Justman JE, El-Sadr W, Sia SK. 2013. Mobile device for disease diagnosis and data tracking in resource-limited settings. Clin Chem 59:629640[CrossRef].[PubMed]
73. Peeling RW, Smith PG, Bossuyt PM. 2006. A guide for diagnostic evaluations. Nat Rev Microbiol 4:S2S6[CrossRef].
74. U.S. Food and Drug Administration. 1997. Design Control Guidance for Medical Device Manufacturers. Doc. No. UCM070642.
75. Pai NP, Pai M. 2012. Point-of-care diagnostics for HIV and tuberculosis: landscape, pipeline, and unmet needs. Discov Med 13:3545.[PubMed]
76. Scott L, Albert H, Gilpin C, Alexander H, DeGruy K, Stevens W. 2014. Multicenter feasibility study to assess external quality assessment panels for Xpert MTB/RIF assay in South Africa. J Clin Microbiol 52:24932499[CrossRef].[PubMed]
77. Nuzzo JB, Rambhia K, Morhard RC, Watson M, Adalja A, Toner E, Cicero AJ, Inglesby TV. 2013. Diagnosing Infection at the Point of Care: How Standards and Market Forces Will Shape the Landscape for Emerging Diagnostic Technologies. Final Report. UPMC Center for Health Security, Baltimore, MD.
78. Schnippel K, Meyer-Rath G, Long L, MacLeod W, Sanne I, Stevens WS, Rosen S. 2012. Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Trop Med Int Health 17:11421151[CrossRef].[PubMed]
79. Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R. 2013. Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev 2:35[CrossRef].[PubMed]

Tables

Generic image for table
TABLE 1

Breakdown of the ASSURED principles for diagnostics development

Citation: Dolinger D, Whalen A. 2016. Molecular Diagnostics and the Changing Face of Point-of-Care, p 545-555. In Persing D, Tenover F, Hayden R, Ieven M, Miller M, Nolte F, Tang Y, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555819071.ch39

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error